Bimekizumab vs. Ustekinumab for kids with plaque psoriasis
Treatments studied
Part of Skin clinical trials.
This study compares two medications—bimekizumab and ustekinumab—for children aged 6 to 17 with moderate-to-severe plaque psoriasis. It aims to see which one is more effective and safe in treating symptoms like thick, scaly patches on the skin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 17 years old
- You have had moderate-to-severe plaque psoriasis for at least 3 months
- Your psoriasis covers at least 10% of your body (like the size of 10 of your own palms)
- Your psoriasis has a severity score of 3 or higher (on a 0–4 scale)
- You weigh at least 33 pounds (15 kg) and are not underweight for your age
- You have not previously been treated with bimekizumab or ustekinumab
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures how much bimekizumab (Bimzelx) gets into breast milk. It helps us understand if the medicine is safe for breastfeeding babies whose mothers take this drug.
This study tests a new drug called vunakizumab to see if it is safe and works well for people with moderate to severe plaque psoriasis. If you have not used biologic treatments before and meet other health requirements, you may be able to join.
This trial tests a daily pill (zasocitinib) for children and teens with moderate to severe plaque psoriasis that hasn't been controlled by other treatments. It aims to see if the pill can safely improve skin symptoms over a long period.
This trial tests how safe and how the body handles (pharmacokinetics) a psoriasis lotion called IDP-122 when used in children with plaque psoriasis. You may be able to join if your child has a suitable amount of plaque psoriasis and can follow safety rules during the study.
This trial tests if the drug bimekizumab can slow down chronic inflammation in people with early plaque psoriasis. It's for adults 18-44 with mild psoriasis who haven't used topical treatments recently.
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
Hear when a new Moderate to Severe Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.